^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Kinisoquin (isoquercetin)

i
Other names: IQC950AN , PR1, quercetin-3-O-glucoside, 482-35-9, CAT IQ
Associations
Company:
Quercis Pharma
Drug class:
AMPK activator, Protein disulphide isomerase inhibitor
Associations
1m
Efficient directional biosynthesis of isoquercitrin from quercetin by Bacillus subtilis CD-2 and its anti-inflammatory activity. (PubMed, Nat Prod Res)
The anti-inflammatory experiments demonstrated strong inhibition of NO release, transcriptional downregulation of classical effective cellular factors tumour necrosis factor-α, interleukin-6, interleukin-1β, and transcriptional upregulation of interleukin-10 in LPS-induced RAW264.7 cells. Its stronger anti-inflammatory activity than quercetin provided a reference for modifying the structure of quercetin to obtain more compounds with better pharmacological activities for medical industry.
Journal
|
IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
Kinisoquin (isoquercetin)
2ms
Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with in silico pharmacokinetic and pharmacodynamic profiles. (PubMed, Front Pharmacol)
Tiliroside (25), boehmenan (30), boehmenan H (31), and isoquercetin (22) elicited the highest binding affinity toward the enzyme with a score of -10.4, -10.4, -10.2 and -10.1 Kcal/mol compared to the reference drug erlotinib having a binding score equal to -9 Kcal/mol...Overall, the current study presents helpful insights into the pharmacokinetic and pharmacodynamic properties of the reported cytotoxic metabolites belonging to family Malvaceae members. The molecular docking and dynamic simulations results intensify the roles of secondary metabolites from medicinal plants in fighting cancer.
PK/PD data • Journal
|
EGFR (Epidermal growth factor receptor)
|
erlotinib • Kinisoquin (isoquercetin)
3ms
Isoquercetin Ameliorates Osteoarthritis via Nrf2/NF-κB Axis: An In Vitro and In Vivo Study. (PubMed, Chem Biol Drug Des)
In vivo, the results of X-ray and SO staining show that intra-articular injection of isoquercetin reduces the degradation of cartilage in the mouse OA model. In conclusion, the present work suggests that isoquercetin may benefit chondrocytes by regulating the Nrf2/NF-κB signaling axis, which supports isoquercetin as a potential drug for the treatment of OA.
Preclinical • Journal
|
IL6 (Interleukin 6) • IL1B (Interleukin 1, beta)
|
Kinisoquin (isoquercetin)
11ms
GPER binding site detection and description: a flavonoid-based docking and molecular dynamics simulations study. (PubMed, J Steroid Biochem Mol Biol)
Therefore, applying pocket and cavity protein detection and docking and molecular dynamics simulations (MD), we generate, from a cluster composed of 39 flavonoids, crucial insights into the potential role as GPER ligands, of Puerarin, Isoquercetin, Kaempferol 3-O-glucoside and Petunidin 3-O-glucoside, aglycones whose sugar moiety delimits a new described sugar-acceptor sub-cavity into the cavity binding site on the receptor, as well as of the probable activation mechanism of the receptor and the pivotal residues involved in it. Altogether, our results shed light on the potential use of the aforementioned flavonoids as GPER ligands and for further evaluations in in vitro and in vivo assays to elucidate their probable anti-cancer activity.
Journal
|
ER (Estrogen receptor)
|
Kinisoquin (isoquercetin)
over1year
Potential Aromatase Inhibitors from Centella asiatica with Non-synonymous SNPs - A Computational Approach. (PubMed, Curr Comput Aided Drug Des)
Our computational analyses predict that the deleterious SNPs did not impact the molecular interactions of Isoquercetin, Quercetin and 9H-Fluorene-2-carboxylic acid, providing better lead compounds for further evaluation as potential aromatase inhibitors.
Journal
|
Kinisoquin (isoquercetin)
2years
Chemopreventive effects and anti-tumorigenic mechanisms of Actinidia arguta, known as sarunashi in Japan toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)- induced lung tumorigenesis in a/J mouse. (PubMed, Genes Environ)
Sar-j and isoQ reduced NNK-induced lung tumorigenesis. Sar-j targets both the initiation and growth/progression steps during carcinogenesis, specifically via anti-mutagenesis, stimulation of alkyl DNA adduct repair, and suppression of Akt-mediated growth signaling. IsoQ might contribute in part to the biological effects of sar-j via suppression of Akt phosphorylation, but it may not be the main active ingredient.
Preclinical • Journal
|
EGF (Epidermal growth factor)
|
Kinisoquin (isoquercetin)
over2years
In vivo, In vitro and Molecular Modelling Analysis of Isoquercetin, Roseoside, Coreximine, Anonaine, and Arianacin Molecules. (PubMed, Curr Comput Aided Drug Des)
As a result of the analysis, the Annona muricata plant has been observed to be effective against cancer and likely to be a potential drug.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
Kinisoquin (isoquercetin)
over2years
Chemical constituents from Carica papaya Linn. leaves as potential cytotoxic, EGFR and aromatase (CYP19A) inhibitors; a study supported by molecular docking. (PubMed, RSC Adv)
Moreover, methyl gallate and nicotiflorin exhibited potential EGFR kinase inhibition activities with an IC of 37.3 ± 1.9 and 41.08 ± 2.1 nM, respectively, compared with the positive control erlotinib (IC = 35.94 ± 1.8 nM)...Clitorin was comparable to the efficacy of the standard drug letrozole (IC = 77.72 ± 4.55)...Clitorin showed the strongest interaction with aromatase (CYP19A1) for the breast cancer receptor with a posing score of -14.2074 and RMSD value of 1.56 Å. Compounds (1-3) possessed a good bioavailability score with a 0.55 value.
Journal
|
EGFR (Epidermal growth factor receptor)
|
erlotinib • letrozole • Kinisoquin (isoquercetin)
almost3years
Antitumor effect of isoquercetin on tissue vasohibin expression and colon cancer vasculature. (PubMed, Oncotarget)
Mice treated with Q3G showed approximately 65% fewer blood vessels than untreated animals and 50% fewer blood vessels than mice treated with bevacizumab. Thus, we show that Q3G has antitumor activity, impairs vascularization, and differentially modulates VASH1 and 2 expressions in colon cancer.
Journal
|
VASH2 (Vasohibin 2)
|
Avastin (bevacizumab) • Kinisoquin (isoquercetin)